XML 28 R10.htm IDEA: XBRL DOCUMENT
v3.23.4

WARRANTS AND NONEMPLOYEE OPTIONS | 12 Months Ended
--- | ---
Sep. 30, 2023
WARRANTS AND NONEMPLOYEE OPTIONS |
WARRANTS AND NON-EMPLOYEE OPTIONS | 4. WARRANTS AND NON-EMPLOYEE OPTIONS The following warrants and non-employee options are outstanding at September 30, 2023:
Warrant/Options |  | Issue Date |  | Shares Issuable upon Exercise of Warrants/ Options |  |  | Exercise Price |  |  | Expiration Date |
Series N |  | 8/18/2008 |  |  | 85,339 |  |  | $ | 3.00 |  |  | 8/18/2024 |
Series UU |  | 6/11/2018 |  |  | 93,603 |  |  | $ | 2.80 |  |  | 6/30/2024 |
Series X |  | 1/13/2016 |  |  | 120,000 |  |  | $ | 9.25 |  |  | 7/13/2024 |
Series Y |  | 2/15/2016 |  |  | 26,000 |  |  | $ | 12.00 |  |  | 8/15/2024 |
Series MM |  | 6/22/2017 |  |  | 333,432 |  |  | $ | 1.86 |  |  | 6/22/2024 |
Series NN |  | 7/24/2017 |  |  | 200,087 |  |  | $ | 2.52 |  |  | 7/24/2024 |
Series RR |  | 10/30/2017 |  |  | 234,009 |  |  | $ | 1.65 |  |  | 10/30/2024 |
Consultant Options |  | 7/28/2017 – 9/2/2023 |  |  | 110,000 |  |  | $ | 1.39 - $2.18 |  |  | 7/27/2027 – 9/1/2028 |
The following warrants and non-employee options are outstanding at September 30, 2022:
Warrant/Options |  | Issue Date |  | Shares Issuable upon Exercise of Warrants/ Options |  |  | Exercise Price |  |  | Expiration Date |
Series N |  | 8/18/2008 |  |  | 85,339 |  |  | $ | 3.00 |  |  | 8/18/2024 |
Series UU |  | 6/11/2018 |  |  | 93,603 |  |  | $ | 2.80 |  |  | 6/30/2024 |
Series X |  | 1/13/2016 |  |  | 120,000 |  |  | $ | 9.25 |  |  | 7/13/2024 |
Series Y |  | 2/15/2016 |  |  | 26,000 |  |  | $ | 12.00 |  |  | 8/15/2024 |
Series MM |  | 6/22/2017 |  |  | 333,432 |  |  | $ | 1.86 |  |  | 6/22/2024 |
Series NN |  | 7/24/2017 |  |  | 200,087 |  |  | $ | 2.52 |  |  | 7/24/2024 |
Series RR |  | 10/30/2017 |  |  | 251,761 |  |  | $ | 1.65 |  |  | 10/30/2022 |
Series SS |  | 12/19/2017 |  |  | 200,000 |  |  | $ | 2.09 |  |  | 12/18/2022 |
Series TT |  | 2/5/2018 |  |  | 600 |  |  | $ | 2.24 |  |  | 2/5/2023 |
Consultant Options |  | 7/28/2017 – 11/18/2020 |  |  | 15,000 |  |  | $ | 2.18 - $11.61 |  |  | 11/17/2022 - 7/27/2027 |
A. Warrant Liabilities There were no warrant liabilities outstanding at September 30, 2023 and 2022. The gains/(losses) on the warrant liabilities for the years ended September 30 are as follows:
|  | 2023 |  |  | 2022 |
Series W warrants |  | $ | - |  |  | $ | - |
Series Z warrants |  |  | - |  |  |  | 64,787 |
Series ZZ warrants |  |  | - |  |  |  | - |
Series AA warrants |  |  | - |  |  |  | 276,035 |
Series BB warrants |  |  | - |  |  |  | - |
Series CC warrants |  |  | - |  |  |  | 24,372 |
Series HH warrants |  |  | - |  |  |  | 1,597 |
Net loss on warrant liabilities |  | $ | - |  |  | $ | 366,791 |
The Company reviews all outstanding warrants in accordance with the requirements of ASC 815 , Accounting for Derivative Instruments and Hedging Activities. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded. In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting periods is recognized as a gain or loss in the statement of operations. Changes in Warrant Liabilities In February 2022, 100,000 Series AA warrants, with an exercise price of $13.75 and 200 Series HH warrants with an exercise price of $3.13, expired. In December 2021, 640 Series CC warrants, with an exercise price of $5.00, expired. In November 2021, 184,800 Series Z warrants, with an exercise price of $13.75, expired. Exercise of Warrant Liabilities No warrants recorded as liabilities were exercised during the year ended September 30, 2023. The following warrants recorded as liabilities were exercised during the year ended September 30, 2022:
Warrants |  | Warrants Exercised |  |  | Exercise Price |  |  | Proceeds |
Series CC |  |  | 15,205 |  |  | $ | 5.00 |  |  | $ | 76,025 |
B. Equity Warrants Changes in Equity Warrants On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary. On June 13, 2022, the expiration dates of the Series N, Series X, Series Y, Series UU, Series MM and Series NN warrants were extended two years. The incremental costs of the Series N, Series X and Series Y warrant extensions were recorded as a deemed dividend and totaled approximately $294,000 for the year ended September 30, 2022. The Series N and Series X warrants are held by the de Clara Trust. The incremental cost of the Series MM, Series NN and Series UU warrant extensions of approximately $635,000 was recorded as a deemed dividend because there were no longer any notes payable associated with these warrants at the time of modification. The Series UU warrants and a portion of the Series MM and Series NN warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust. Exercise of Equity Warrants The following equity warrants were exercised during the year ended September 30, 2023.
Warrants |  | Warrants Exercised |  |  | Exercise Price |  |  | Proceeds |
Series RR |  |  | 17,752 |  |  | $ | 1.65 |  |  | $ | 29,291 |
Series SS |  |  | 200,000 |  |  |  | 2.09 |  |  |  | 418,000 |
|  |  | 217,752 |  |  |  |  |  |  | $ | 447,291 |
The following equity warrants were exercised during the year ended September 30, 2022.
Warrants |  | Warrants Exercised |  |  | Exercise Price |  |  | Proceeds |
Series NN |  |  | 10,000 |  |  | $ | 2.52 |  |  | $ | 25,200 |
C. Options and Shares Issued to Consultants The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2023 and 2022, the Company issued 249,997 and 156,547 shares, respectively, of common stock to consultants, all of which were restricted shares. Under these arrangements, during the periods presented, the common stock was issued with stock prices ranging from $1.26 to $11.20 per share. The weighted average grant price was $1.83 and $4.59, respectively, for stock issued during the years ended September 30, 2023 and 2022. During the years ended September 30, 2023 and 2022, the Company recorded total expense of approximately $656,000 and $762,000, respectively, relating to these consulting agreements. At September 30, 2023 and 2022, costs of approximately $205,000 and $295,000, respectively, are included in prepaid expenses. During the year ended September 30, 2023, the Company issued 100,000 options to a consultant to purchase common stock with an exercise price of $1.39. These options vest 50% on September 2, 2024 and 50% on September 2, 2025 and expire on September 1, 2028. No options were issued to consultants during the year ended September 30, 2022. As of September 30, 2023, 110,000 options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option Plan.

X
- References No definition available. + Details
Name: | cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock
Namespace Prefix: | cvm_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | cvm_WarrantsAndNonemployeeOptionsAbstract
Namespace Prefix: | cvm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration